FDA TO ACCELERATE DRUG TRIALS WITH AI AND REAL-TIME DATA

The Food and Drug Administration is moving to shorten drug development cycles by accessing clinical trial data as tests progress rather than waiting for completion. This shift toward real-time monitoring enables regulators to identify trends, safety concerns, and efficacy signals earlier in the process. Artificial intelligence will play a key role in analyzing the continuous data streams, helping the FDA spot patterns that might take months or years to surface through traditional methods. The approach reduces redundant testing phases and allows for faster decision-making on drug candidates. The initiative addresses a critical bottleneck in pharmaceutical development. Current drug approval timelines typically span years of testing before submission for regulatory review. By integrating AI-driven analytics and live data feeds, the FDA expects to maintain safety standards while cutting unnecessary delays. The move could benefit patients awaiting treatments for serious conditions while encouraging pharmaceutical companies to invest in development. Implementation details and rollout timeline remain under development.